FDA advisory panel recommends approval of biosimilar Remicade

February 9, 2016 10:33 PM

21 0

Feb 9 A medical advisory panel to the U.S. Food and Drug Administration on Tuesday recommended approval of a biosimilar form of Johnson & Johnson's Remicade arthritis drug, deciding it was highly similar to the blockbuster branded product.

The independent panel determined that clinical trials of the biosimilar from Celltrion Inc and Pfizer Inc , called Remsima, showed no clinically meaningful differences between it and Remicade in treatment of rheumatoid arthritis and a related condition called ankylosing spondylitis.

Read more

To category page